Pharmafile Logo
Pharmafocus logo
Advanced Search

Thalidomide

Showing 6 posts of 6 posts found.

celgene_1_02_1

NICE won’t back Revlimid in new setting

July 31, 2014
Medical Communications, Sales and Marketing Celgene, NICE, Revlimid, Thalidomide, multiple myeloma

NICE has once again said it does not think that Celgene’s rare cancer drug Revlimid should be used on the …

News
Celgene image

Celgene ‘downplayed’ Thalomid, Revlimid risks

February 7, 2014
Medical Communications, Sales and Marketing Celgene, Revlimid, Thalidomide, thalomid

A former sales representative for US pharma firm Celgene is accusing her old company of promoting two of its key …

News
Janssen's Velcade (bortezomib)

NICE recommends thalidomide ahead of Velcade

July 27, 2011
Sales and Marketing NICE, Thalidomide, Velcade

NICE has recommended Celgene’s thalidomide ahead of J&J’s Velcade for multiple myeloma. Celgene’s drug is recommended in combination with an …

News

NICE backs Celgene’s thalidomide and Janssen’s Velcade

June 21, 2011
Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma

Celgene’s thalidomide and Janssen-Cilag’s Velcade have been given the thumbs up by NICE as a treatment for a cancer that …

News
Velcade

Janssen to appeal against Velcade decision

August 26, 2010
Medical Communications, Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma

Celgene’s Thalidomide has been recommended by NICE for multiple myeloma ahead of Janssen-Cilag’s Velcade. A final appraisal determination says that …

News

Celgene

January 1, 2010
Research and Development, Sales and Marketing Abraxane, Celgene, Revlimid, Thalidomide

Founded in 1986, Celgene was created as a spin off from the Celanese Corporation. Two years later, the company received …

Feature

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024